Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of <scp>sG</scp>alectin‐1, <scp>sCD</scp>163 and <scp>sCD</scp>30 with TARC

Plattel, Wouter J.; Alsada, Z; Imhoff, Gustaaf W. van; Diepstra, Arjan; Berg, Anke van den; Visser, Lydia

doi:10.1111/bjh.14317

Cited by 41 publications

(52 citation statements)

References 33 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that miRs tended to reach the levels of those found in controls. In addition, the levels of sCD14 and sCD30 remained higher compared to the control group but decreased after chemotherapy, which is also in agreement with other studies [62,64].…”

Section: Discussionsupporting

confidence: 92%

Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21

Hernández-Walias

Vázquez

Pacheco

et al. 2020

JCM

View full text Add to dashboard Cite

The incidence of classical Hodgkin lymphoma (cHL) in the HIV-1 setting has increased 5–25-fold compared to that observed in the general population. This study aimed to determine whether selected micro RNAs (miRs) and other soluble biomarkers and cellular subsets are dysregulated in cHL and could be used as biomarkers. This was a retrospective and longitudinal matched case-control study of 111 Caucasian, HIV-1-infected adult individuals, including 37 individuals with cHL and 74 with no type of cancer. Immunovirological data, plasma exosome-derived miR-16, miR-20a, miR-21, miR-221, miR-223, miR-106a, miR-185, miR-23, miR-30d, miR-222, miR-146a and miR-324, plasma IL-6, sCD14, sCD27, sCD30, sIL-2R, TNFR1, and cell phenotyping of T and B lymphocytes and natural killer (NK) cells were analyzed. Before cHL diagnosis, miR-20a, miR-21, and sCD30 were higher in cHL (p = 0.008, p = 0.009 and p = 0.042, respectively), while miR-16 was down-regulated (p = 0.040). miR-20a and miR-21 were independently associated with cHL (p = 0.049 and p = 0.035, respectively). The combination of miR-20a and miR-21 showed a good AUC value of 0.832 with a moderate likelihood ratio positive (LR+) value of 5.6 and a slight likelihood ratio negative (LR−) value of 0.23. At cHL diagnosis, miR-20a, miR-21 and miR-324 were overexpressed in cHL (p = 0.005, p = 0.024, and p = 0.001, respectively), while miR-223, miR-16, miR-185 and miR-106a were down regulated (p = 0.042, p = 0.007, p = 0.006, and p = 0.002, respectively). In addition, sCD14, sCD27, sCD30 and IL2R levels were higher in these individuals (p = 0.038, p = 0.010, p = 0.030, p = 0.006, respectively). miR-20a was independently associated with cHL (p = 0.011). The diagnostic value of miR-20a showed good AUC value of 0.754 (p = 0.074) with a slight LR+ value of 2 and a slight LR− of 0.25. After chemotherapy, miR-20a was higher in those individuals who had an adverse outcome (p < 0.001), while sCD14 and sCD30 were higher (p < 0.001). A specific signature of miRs and cytokines associated with a subsequent cHL diagnosis was found in this study, especially miR-20a and miR-21. Also, another biomarker signature was found at cHL diagnosis, with a relevant discriminant disease value for miR-20a. Of note, miR-20a expression was higher in those individuals who had an adverse clinical outcome after chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 92%

Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21

Hernández-Walias

Vázquez

Pacheco

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Regarding the survival parameters, we found that the Kyn/Trp ratio was significantly associated with PFS, whereas none of the seven component factors of the IPS for advanced HL, nor the serum sCD30 level, was significantly associated with PFS. This observation that only the serum Kyn/Trp ratio was significantly associated with shorter PFS should attract attention because it indicates the importance of Trp catabolism in the pathogenesis of HL.…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the survival parameters, we found that the Kyn/Trp ratio was significantly associated with PFS, whereas none of the seven component factors of the IPS for advanced HL, 17 nor the serum sCD30 level, [26][27][28][29][30] Most research in this area to date has focused on IDO as the central and immunobiologically relevant enzyme that catalyzes the conversion of Trp to Kyn. However, there are two other enzymes, tryptophan 2,3dioxygenase and IDO2, that also catalyze the same enzymatic step.…”

mentioning

confidence: 92%

Clinical significance of tryptophan catabolism in Hodgkin lymphoma

et al. 2017

View full text Add to dashboard Cite

Indoleamine 2,3‐dioxygenase 1 (IDO) is an enzyme catabolizing tryptophan (Trp) into the kynurenine (Kyn) pathway. The purpose of the present study was to determine the clinical significance of Trp catabolism in newly diagnosed Hodgkin lymphoma (HL) patients. We quantified serum Trp and Kyn in 52 HL patients, and analyzed their associations with different clinical parameters including serum soluble CD30 concentration. The IDO expression was evaluated in the patients’ affected lymph nodes. The cohort comprised 22 male and 30 female patients (age range, 15‐81 years; median, 45 years), with a 5‐year overall survival (OS) of 88.6%. The OS was significantly shorter for patients with a high Kyn/Trp ratio (OS at 5 years, 60.0% vs 92.2%), for those with stage IV disease, and for those with lymphocytopenia (<600/mm3 and/or <8% white blood cell count). The latter two parameters are components of the international prognostic score for advanced HL. In contrast, there were no significant differences in OS according to age, serum albumin, hemoglobin, sex, white blood cell count, or serum soluble CD30 (≥ or <285.6 ng/mL). Multivariate analysis using the three variables stage, lymphocytopenia, and serum Kyn/Trp ratio showed that only the latter significantly affected OS. Indoleamine 2,3‐dioxygenase 1 was produced by macrophages/dendritic cells, but not by HL tumor cells, and IDO levels determined by immunohistochemistry had a significant positive correlation with the serum Kyn/Trp ratio. In conclusion, quantification of serum Kyn and Trp is useful for predicting prognosis of individual HL patients.

show abstract

“…Blood-based biomarkers are ideally suited to provide answers to those questions; for example, serum TARC, galectin-1, and CD163 have emerged as promising tools to assess interim response to chemotherapy in addition to PET. 136,137 Moreover, detection of tumor-specific mutations or CN variations in cell-free circulating tumor DNA by next-generation sequencing techniques or digital droplet polymerase chain reaction have been shown to be feasible in patients with cHL and provide unique opportunities for real-time disease monitoring and quantitative assessment of minimal residual disease. [138][139][140]…”

Section: Biomarker-driven Prognostication and Risk Stratification In Chlmentioning

confidence: 99%

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies

Mottok

Steidl

2018

Blood

View full text Add to dashboard Cite

Hodgkin lymphoma is considered a prime example of treatment success, with cure rates exceeding 80% using modern combined modality therapies. However, especially in adolescents and young adults, treatment-related toxicity and long-term morbidity still represent persistent challenges. Moreover, outcomes in patients with relapsed or refractory disease remain unfavorable in the era of high-dose chemotherapy and stem-cell transplantation. Hence, there is a high demand for novel and innovative alternative treatment approaches. In recent years, many new therapeutic agents have emerged from preclinical and clinical studies that target molecular hallmarks of Hodgkin lymphoma, including the aberrant phenotype of the tumor cells, deregulated oncogenic pathways, and immune escape. The antibody-drug conjugate brentuximab vedotin and immune checkpoint inhibitors have already shown great success in patients with relapsed/refractory disease, leading to US Food and Drug Administration approval and new trials testing these agents in various clinical settings. The expanding knowledge and understanding of Hodgkin lymphoma biology and disease progression, as well as the development of robust tools for biomarker-driven risk stratification and therapeutic decision making, continue to be fundamentally important for the success of these and other novel agents. We anticipate that the availability and clinical implementation of novel molecular assays will be instrumental in an era of rapid shifts in the treatment landscape of this disease. Here, we review the current knowledge of Hodgkin lymphoma pathobiology, highlighting the related development of novel treatment strategies and prognostic models that hold the promise to continually challenge and change the current standard of care in classical Hodgkin lymphoma.

show abstract

Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‐1, sCD163 and sCD30 with TARC

Cited by 41 publications

References 33 publications

Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21

Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21

Clinical significance of tryptophan catabolism in Hodgkin lymphoma

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies

Contact Info

Product

Resources

About